10-Q: Exagen Inc. Reports First Quarter 2025 Financial Results, Revenue Up 7.5% Year-Over-Year

Exagen Inc. announces its financial results for the first quarter of 2025, highlighting a 7.5% increase in revenue compared to the same period last year and securing a new term loan facility.

Summary

• Exagen Inc. reported a 7.5% increase in revenue for the three months ended March 31, 2025, reaching $15.498 million compared to $14.415 million in 2024.
• The company's net loss for the quarter was $(3.752) million, or $(0.20) per share, compared to a net loss of $(3.360) million, or $(0.19) per share, for the same period in the previous year.
• Gross margin decreased slightly to 58.9% from 59.6% in the prior year.
• Operating expenses increased to $12.488 million from $11.601 million year-over-year.
• As of March 31, 2025, Exagen had cash and cash equivalents of $11.2 million and an accumulated deficit of $298.1 million.
• On April 25, 2025, Exagen entered into a credit agreement with Perceptive for a term loan facility of up to $75.0 million, with an initial tranche of $25.0 million used to repay the 2017 Term Loan.
• The company is focused on expanding the adoption of its AVISE CTD test and developing innovative testing products.
• Exagen expects to commercially launch its peptidyl arginine deiminase 4 (PAD4) biomarker around the end of this year.
• The company is also developing tests for Lupus Nephritis biomarkers, SLE Disease Activity, RA Disease Activity, and Kidney Damage Biomarkers.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While revenue growth and new financing are positive, the net loss and accumulated deficit temper the overall outlook. The company is making progress but still faces challenges.

Positives

• Revenue increased by 7.5% year-over-year, driven by ASP expansion and, to a lesser extent, an increase in test volume.
• The company secured a new term loan facility with Perceptive, enhancing its liquidity position and providing additional financial flexibility.
• Exagen is actively developing new testing products and enhancements to existing products, which could drive future growth.
• The company is focused on achieving sustainable profitable growth through gross margin enhancements and improved operating expense efficiencies.
• The court granted Exagen's motion to dismiss with prejudice and denied the relator's motion for leave to amend in March 2025 in relation to legal proceedings.

Negatives

• The company incurred a net loss of $(3.752) million for the quarter.
• Gross margin decreased slightly to 58.9% from 59.6% in the prior year.
• As of March 31, 2025, the company had an accumulated deficit of $298.1 million.
• The company is still facing challenges relating to commercial payor claim processing and revenue.

Risks

• The company's ability to achieve broad coverage and reimbursement for its tests from third-party payors is critical to its revenue.
• Changes in U.S. trade policy and the impact of tariffs may have a material adverse effect on the company's business.
• The company's term loan contains restrictions that limit its flexibility in operating its business.
• The company may not be able to generate sufficient cash flow or revenue to meet the financial covenants or pay the principal and accrued interest on its debt.
• The relator filed an appeal with respect to the court ruling in March 2025, and the company cannot predict the outcome of such an appeal.

Future Outlook

Exagen expects to continue to invest in research and development to develop additional testing products and is focused on achieving sustainable profitable growth through gross margin enhancements and improved operating expense efficiencies. The company believes that its existing cash and cash equivalents and its anticipated future revenue will be sufficient to meet its anticipated cash requirements for at least the next 12 months from the date of this filing.

Management Comments

• Under the leadership of our Chief Executive Officer, John Aballi, who joined Exagen in October 2022, we are executing an operational turnaround of the business, resulting in a return to revenue growth and gross margin expansion while significantly reducing operating expenses and cash burn.
• We believe our strong focus and extensive background in the field of rheumatology, combined with our commitment to exceptional customer service and support, position us well to respond to the needs of rheumatologists, primary care physicians, other specialists, and the patients they serve.

Industry Context

Exagen operates in the medical technology industry, specifically focusing on diagnostic testing for rheumatic, autoimmune, and autoimmune-related diseases. The company's performance is affected by factors such as reimbursement rates from payors, adoption of its testing products by healthcare providers, and regulatory changes affecting laboratory developed tests (LDTs). The company faces competition from other diagnostic testing companies and must continue to innovate and demonstrate the clinical utility of its products to maintain its market position.

Comparison to Industry Standards

• Exagen's focus on autoimmune disease diagnostics aligns with the broader trend of personalized medicine and the increasing demand for specialized testing.
• Companies like Myriad Genetics and Quest Diagnostics also offer specialized diagnostic tests, but Exagen differentiates itself through its focus on rheumatology and its AVISE-branded tests.
• The company's gross margin of 58.9% is comparable to other diagnostic testing companies, but its net loss indicates that it is still in a growth phase and investing heavily in research and development.
• The new Perceptive Term Loan Facility is similar to financing arrangements used by other companies in the industry to fund growth and acquisitions.

Legal Proceedings

• The court granted Exagen's motion to dismiss with prejudice and denied the relator's motion for leave to amend in March 2025.
• The relator filed an appeal with respect to this ruling, and the company intends to vigorously defend against the appeal.

Stakeholder Impact

• Shareholders: The revenue growth and new financing are positive for shareholders, but the net loss and accumulated deficit are concerns.
• Employees: The company's growth and development of new products could create opportunities for employees.
• Customers: The company's focus on innovation and clinical utility could lead to improved diagnostic testing options for patients.
• Suppliers: The company's supply agreements are important for ensuring a reliable supply of reagents and other materials.
• Creditors: The new term loan facility with Perceptive is a significant event for creditors.

Next Steps

• Commercially launch the PAD4 biomarker around the end of this year.
• Continue development of tests for Lupus Nephritis biomarkers, SLE Disease Activity, RA Disease Activity, and Kidney Damage Biomarkers.
• Focus on expanding the adoption of AVISE CTD and achieving sustainable profitable growth.
• Monitor and respond to any regulatory changes affecting laboratory developed tests (LDTs).

Key Dates

Keywords

Exagen, AVISE CTD, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Autoimmune Disease, Diagnostic Testing, Financial Results, Revenue, Biomarkers, Perceptive Term Loan